Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

18.79
-0.4300-2.24%
Post-market: 19.150.3600+1.92%19:34 EDT
Volume:1.67M
Turnover:31.88M
Market Cap:1.98B
PE:-14.28
High:19.73
Open:19.39
Low:18.66
Close:19.22
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.66
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.30
PE(LYR):-2.64

Loading ...

Sarepta Therapeutics - FDA Sets Pdufa Target Action Date of February 28, 2027

THOMSON REUTERS
·
Jun 30

Sarepta Announces FDA Acceptance of Sndas for Amondys 45® and Vyondys 53®

THOMSON REUTERS
·
Jun 30

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Eli Lilly & Co (LLY) and C4 Therapeutics (CCCC)

TIPRANKS
·
Jun 22

Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
Jun 22

Sarepta Therapeutics (SRPT) Stock Could Be 19% Undervalued As Elevidys Outlook Steadies

Simply Wall St.
·
Jun 21

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

MT Newswires Live
·
Jun 18

Is Sarepta Therapeutics (SRPT) Quietly Rewriting Its Risk Profile With New Equity Plans And Q1 Profitability?

Simply Wall St.
·
Jun 08

A Look At Sarepta Therapeutics (SRPT) Valuation After New Shelf Registration For Potential Share Offering

Simply Wall St.
·
Jun 06

Sarepta Therapeutics shareholders approve 2026 equity incentive plan at annual meeting

Reuters
·
Jun 05

SRPT Expands Into Huntington’s Disease With New First-in-Human Trial

TIPRANKS
·
Jun 05

Acting US FDA chief meets with rare disease groups to mend fences

Reuters
·
Jun 04

Sarepta Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 02

A Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness And ELEVIDYS Safety Concerns

Simply Wall St.
·
May 27

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

TIPRANKS
·
May 19

Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says

MT Newswires Live
·
May 15

Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged

TIPRANKS
·
May 15

Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026

TIPRANKS
·
May 11

Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says

MT Newswires Live
·
May 09

Sarepta Therapeutics Shares Down 3.3% After Lower Q1 Sales for Gene Therapy

THOMSON REUTERS
·
May 07

H.C. Wainwright Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
May 07